History
  • No items yet
midpage
21-55370
9th Cir.
Mar 9, 2022
Read the full case

Background

  • Sentynl Therapeutics, an opioid drug maker, received federal subpoenas (2018–2019) in an investigation into illegal profits from opioids.
  • Sentynl sought reimbursement under its directors, officers and organization (D&O) policy issued by U.S. Specialty for costs of complying with the subpoenas.
  • U.S. Specialty denied the claim based on a policy exclusion for "Loss in connection with a Claim arising out of ... any goods or products manufactured, ... sold, marketed, distributed ... by [Sentynl]."
  • Sentynl sued for breach of contract and breach of the implied covenant of good faith; the district court granted summary judgment for U.S. Specialty.
  • The Ninth Circuit reviewed de novo and affirmed, holding the subpoena-compliance costs were excluded because the subpoenas arose out of Sentynl’s opioid products.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Are subpoena-compliance costs covered despite the goods/products exclusion? Subpoenas are investigatory, not claims "arising out of" products. Subpoenas target companies in the opioid market and therefore arise from Sentynl’s products. Exclusion applies; costs not covered.
How should "arising out of" be interpreted? Ambiguous; exclusion should be narrowly construed against insurer (Partridge). Phrase is broad and excludes risks with even a slight connection. "Arising out of" is broad, not ambiguous; construed to mean originating from/flowing from.
Does the exclusion require a product defect or characteristic? Exclusion should be limited to defects/characteristics of the product. Exclusion covers broader connections, including marketing/statements about products. Exclusion is not limited to defects; it reaches claims about what seller said/did about products.
Does the exclusion render coverage illusory? A broad exclusion eliminates meaningful coverage. Exclusion does not eliminate all coverage; other claim types remain covered. No; exclusion does not render coverage illusory because it does not wipe out all policy coverage.

Key Cases Cited

  • Trishan Air, Inc. v. Federal Ins. Co., 635 F.3d 422 (9th Cir. 2011) (standard of de novo review for summary judgment issues in insurance disputes)
  • Continental Cas. Co. v. City of Richmond, 763 F.2d 1076 (9th Cir. 1985) (defines "arising out of" broadly as originating from/flowing from)
  • Southgate Recreation & Park Dist. v. Cal. Assn. for Park & Recreation Ins., 106 Cal. App. 4th 293 (Cal. Ct. App. 2003) (California treats "arising out of" as requiring only a slight connection)
  • State Farm Mut. Auto. Ins. Co. v. Partridge, 514 P.2d 123 (Cal. 1973) (ambiguities in exclusions are construed narrowly against insurer)
  • Travelers Prop. Cas. Co. of Am. v. Actavis, Inc., 16 Cal. App. 5th 1026 (Cal. Ct. App. 2017) (goods/products exclusion can cover claims about seller representations and marketing)
  • Los Angeles Lakers, Inc. v. Federal Ins. Co., 869 F.3d 795 (9th Cir. 2017) (give effect to parties' intent in light of broad exclusions)
  • Safeco Ins. Co. of Am. v. Robert S., 28 P.3d 889 (Cal. 2001) (coverage is only illusory if an exclusion entirely eliminates coverage)
  • Giles v. Gen. Motors Acceptance Corp., 494 F.3d 865 (9th Cir. 2007) (standard for predicting how state high court would decide unsettled state-law issues)
Read the full case

Case Details

Case Name: Sentynl Therapeutics, Inc. v. U.S. Specialty Insurance Co
Court Name: Court of Appeals for the Ninth Circuit
Date Published: Mar 9, 2022
Citation: 21-55370
Docket Number: 21-55370
Court Abbreviation: 9th Cir.
Log In